16 research outputs found
PCN116 Cost-Effectiveness of Denosumab Versus Zoledronic Acid (ZA) for the Prevention of Skeletal-related Events (SRE) in Patients with Bone Metastases from Solid Tumors in the Netherlands
Get PDFFinal results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
Get PDFPatient-Reported Outcomes Assessed Using the Breast-Q Instrument in Women Undergoing Breast Reconstruction Post-Mastectomy: A Systematic Literature Review
No full text
Complications, costs And Resource Utilization in Real-World Complex Abdominal Wall Reconstruction Patients
No full textPMD74 Effects of Autologous fat grafting systems on inpatient operating room time and costs: a Hospital budget impact analysis
Get PDFPCN132 MODELING THE LIFETIME EFFECTIVENESS OF DENOSUMAB AND ZOLEDRONIC ACID (ZA) IN THE PREVENTION OF SKELETAL RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTASES FROM SOLID TUMORS
Get PDFPCN132 MODELING THE LIFETIME EFFECTIVENESS OF DENOSUMAB AND ZOLEDRONIC ACID (ZA) IN THE PREVENTION OF SKELETAL RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTASES FROM SOLID TUMORS
No full textPhysician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims
No full textAdherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate
No full textIn this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly, then crossed over to the other treatment. The primary endpoint, treatment adherence at 12 months, was 76.6% for alendronate and 87.3% for denosumab
